[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:esophageal-carcinoma:prolyl-endopeptidase-fap":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Esophageal Carcinoma","Prolyl Endopeptidase FAP",3,[8,16,23],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06710756","Lead-212 PSV359 Therapy for Patients With Solid Tumors",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:19:10.436356Z","2026-05-05T02:43:28.400599Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07213791","A Study of LY4337713 in Participants With FAP-Positive Solid Tumors",[20],"Phase 1","2026-08-26T02:17:13.277148Z","2026-05-05T02:43:28.120672Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT05547321","Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.",[20],"2026-08-26T02:15:54.846520Z","2026-05-05T02:43:28.476219Z"]